PCSK9 Inhibitors

Alirocumab - Bococizumab - Evolocumab      

Select            
Trial Studied trt Control trt patientstagsROB Trial resultserious adverse events death from all causes as adverse event

cardiovascular prevention

alirocumab
ODYSSEY OPTIONS I   alirocumabezetimibe (on top statin)negative-44%-100%
ODYSSEY OPTIONS II   alirocumabezetimibe (on top statin)negative-26%-100%
ODYSSEY MONO      NCTalirocumabezetimibe aloneLow risk of bias negative-2%
ODYSSEY Long-Term, 2015      NCTalirocumabplacebo (on top statins)Exploratory suggesting -4%-71%
ODYSSEY Alternative      NCTalirocumabplacebo (on top statins)Low risk of bias negative19%
ODYSSEY OUTCOMES, 2018      NCTalirocumabplacebo (on top statins)Low risk of bias conclusive
ODYSSEY FH 1      NCTalirocumabplacebo (on top statins)Low risk of bias -
ODYSSEY FH 2      NCTalirocumabplacebo (on top statins)Low risk of bias -
ODYSSEY HIGH FH      NCTalirocumabplacebo (on top statins)negative-3%
ODYSSEY COMBO        NCTalirocumabplacebo (on top statins)Low risk of bias negative-5%-49%
ODYSSEY COMBO II        NCTalirocumabplacebo (on top statins)Low risk of bias negative5%-50%
evolocumab
MENDEl 2    NCTevolocumab -
Mendel 1, 2012      NCTevolocumab -
YUKAWA-1, 2014   evolocumab -
GAUSS 2    NCTevolocumabezetimibe alonenegative 201%
GAUSS 1, 2012    NCTevolocumabplacebonegative+Infini%
DESCARTES, 2014    NCTevolocumabplacebo (on top statins)negative28%+Infini%
LAPLACE-TIMI 57    NCTevolocumabplacebo (on top statins) -
RUTHERFORD-1    NCTevolocumabplacebo (on top statins)negative+Infini%
LAPLACE 2, 2014    NCTevolocumabplacebo (on top statins)negative-12%-100%
RUTHERFORD-2, 2015    NCTevolocumabplacebo (on top statins)negative-31%
FOURIER, 2017      NCTevolocumabplacebo (on top statins)Low risk of bias conclusive